Get the Stockscreener App
8.61
4.87%
0.40
After Hours:
8.40
-0.21
-2.44%
Armata Pharmaceuticals Inc stock is traded at $8.61, with a volume of 35,713.
It is up +4.87% in the last 24 hours and down -19.00% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$8.21
Open:
$8.45
24h Volume:
35,713
Relative Volume:
0.78
Market Cap:
$313.46M
Revenue:
$5.05M
Net Income/Loss:
$-46.90M
P/E Ratio:
-6.5079
EPS:
-1.323
Net Cash Flow:
$-27.43M
1W Performance:
+0.82%
1M Performance:
-19.00%
6M Performance:
+188.93%
1Y Performance:
+412.50%
1-Day Range:
$8.3078
$9.5199
1-Week Range:
$7.4301
$9.5199
52-Week Range:
$0.8981
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
8.61 | 298.90M | 5.05M | -46.90M | -27.43M | -1.323 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Armata Pharmaceuticals (ARMP) Q4 and Full-Year 2025 Earnings: Revenue Beat, Net Loss Hits $173.8M - Bayelsa Watch
Breakout Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stockPrice Action & AI Powered Market Trend Analysis - baoquankhu1.vn
ARMATA PHARMACEUTICALS, INC._December 31, 2025 - SEC.gov
ARMP Reports Decrease in Grant Revenue for Q4 2025 - GuruFocus
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - PR Newswire
ARMP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Armata Pharmaceuticals Reports Positive Phase 2a Study Results - MSN
HC Wainwright reaffirms buy on Armata Pharmaceuticals, Inc. (ARMP) after FDA nod - MSN
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval By Investing.com - Investing.com India
Armata Pharmaceuticals (ARMP) Delays Financial Results Release - GuruFocus
Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update - marketscreener.com
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval - Investing.com
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Finviz
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay - TipRanks
Armata Pharmaceuticals delays 2025 results, wins QIDP and readies Phase 3 for AP-SA02 - TradingView
Armata Pharmaceuticals (ARMP) delays 2025 results, advances AP-SA02 toward Phase 3 - Stock Titan
Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan
شركة أرماتا للأدوية تؤجل الإعلان عن نتائج الربع الرابع والعام 2025 بالكامل، وتقدم تحديثاً عن الشركة. - Sahm
Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition - Stock Titan
Armata (ARMP) CEO Birx has 4,919 RSU shares withheld for tax obligations - Stock Titan
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday - MarketBeat
Director at Armata (NASDAQ: ARMP) receives 25,640 stock options grant - Stock Titan
Armata (NASDAQ: ARMP) director receives 25,640 stock options at $11.61 strike - Stock Titan
[Form 4] Armata Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Armata Pharmaceuticals (ARMP) grants director 25,640 stock options - Stock Titan
Armata Pharmaceuticals (ARMP) director receives grant of 25,640 stock options - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Published on: 2026-03-08 06:18:18 - baoquankhu1.vn
Will Armata Pharmaceuticals Inc. stock return to pre crisis levelsNew Guidance & Risk Controlled Swing Alerts - Naître et grandir
New Strong Sell Stocks for April 24th - MSN
Will Armata Pharmaceuticals Inc. stock outperform growth indexesQuarterly Portfolio Summary & Verified Technical Trade Signals - Naître et grandir
ARMPAmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split - mx.advfn.com
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Yahoo Finance
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX - RTTNews
ARMP Should I Buy - Intellectia AI
Armata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30 - Nasdaq
H.C. Wainwright lowers Armata Pharmaceuticals stock price target to $15 By Investing.com - Investing.com Canada
ARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus
Armata Pharmaceuticals (ARMP) Receives FDA Designation for AP-SA - GuruFocus
Armata Pharmaceuticals stock gains on FDA designation By Investing.com - Investing.com Canada
Armata Pharmaceuticals stock gains on FDA designation - Investing.com India
Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment - marketscreener.com
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy - TipRanks
Armata Pharmaceuticals receives FDA qualified infectious disease product designation - marketscreener.com
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation - TradingView
Armata Pharmaceuticals wins FDA QIDP for AP-SA02, enabling 5 years exclusivity and Fast Track eligibility - TradingView
FDA grants QIDP designation to Armata (ARMP) phage therapy AP-SA02 - Stock Titan
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PR Newswire
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):